

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 06275-0512US1	Application No. 10/580,589
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Philippe Rogueda	
		Filing Date May 25, 2006	Group Art Unit 1616

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/J.H.A.A./	1	4,579,854	04/01/86	Iwakuma et al.			
	2						
	3						
	4						
	5						

Eng.
Equiv.
Abs.
Only

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/J.H.A.A./	6	DE 4129535	03/12/93	Germany				
/J.H.A.A./	7	DE 10205087	08/21/03	Germany				
/J.H.A.A./	8	WO02/12265	02/14/02	WIPO				
/J.H.A.A./	9	WO02/12266	02/14/02	WIPO				
/J.H.A.A./	10	WO02/88167	10/03/02	WIPO				
/J.H.A.A./	11	WO02/76933	11/07/02	WIPO				
/J.H.A.A./	12	WO03/066031	08/14/03	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/J.H.A.A./	13	Steckel, H. et al., "A Novel Formulation Technique for metered Dose Inhaler (MDI) Suspensions", International Journal of Pharmaceutics, Amsterdam, NL, Vol. 284, No. 1-2, (2004), pp. 75-82.
/J.H.A.A./	14	Williams III, R.O. et al., "Influence of Formulation Technique for Hydroxypropyl-Beta-Cyclodextrin on the Stability of Aspirin in HFA 134a", European Journal of Pharmaceutics and Biopharmaceutics, Elsevier Science Publishers B.V., Amsterdam, NL, Vol. 47, No. 2, (1999), pp. 145-152.
	15	
	16	

Examiner Signature /James Alstrum Acevedo/	Date Considered 05/03/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	